Accumulating evidence has indicated that p53 mutation, including the hotspot mutations (R175H, R248W and R273H)[11],[12], not only lose the tumor suppression activity of widetype p53, but also gain novel oncogenic activities to promote tumorigenesis and drug resistance[13],[14]. Here, TP53 is linked to neoplasm.